ELUTIA INC. (ELUT): Entry into a Material Definitive Agreement
ELUTIA INC. (ELUT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2620864d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGI
How this was made
The 30-second read
Why it matters
For ELUT, the key trading question is how the deal changes expected cash proceeds, contingent earnout value, and risk of non-closing, plus any operational transition obligations post-close.
Market read
A signed, material asset sale agreement is a concrete corporate event that can drive repricing, but the excerpt omits the purchase price and earnout details needed for valuation.
What to watch
Traders should verify the purchase price, earnout structure, transition services, restrictive covenants, and any termination rights or conditions to closing, which are not shown in the excerpt.
Background
The 8-K reports Item 1.01, entry into a material definitive agreement, attaching an asset purchase agreement dated July 16, 2026 between Cellution Biologics (buyer) and Elutia (seller).
Ticker impact
Elutia entered a material definitive asset purchase agreement to sell its SimpliDerm hADM business to Cellution Biologics, per 8-K Item 1.01.
Near-term volatility is likely around deal headlines, but direction depends on disclosed economics and closing conditions not included in the excerpt.
This is a primary SEC 8-K disclosure of a signed asset purchase agreement. However, the provided text does not include the purchase price, earnout amounts, or key closing milestones, limiting conviction on valuation impact.
Market effects
Signals consolidation in acellular dermis (hADM) breast reconstruction product commercialization, potentially affecting competitive positioning and supply relationships.
No clear regional market linkage from the excerpt.
Limited global read-through; impact is primarily company-specific unless additional regulatory or distribution details emerge.
Counterpoint
A signed agreement does not guarantee closing; if economics are unfavorable or regulatory/contract consents are difficult, the market may discount the deal rather than reward it.
Key entities
- issuerELUTIA INC.
Seller in the asset purchase agreement for the SimpliDerm hADM business.
- buyerCellution Biologics Inc.
Buyer acquiring specified assets and assuming limited executory obligations related to periods after closing.
